DotLab

DotLab is a biotechnology company specializing in innovative diagnostics for endometriosis with a focus on non-invasive testing solutions that enhance patient care. Founded in 2016, DotLab is based in San Francisco, US, and is dedicated to developing diagnostic tools for women's health. The company has raised a total of USD 10. 00 mn through its Series A funding round on June 25, 2019, led by The Cooper Companies, Inc.

, with participation from Luxor Capital Group, Tiger Global Management, and Wilson Sonsini Goodrich & Rosati. CEO Szenci Attila oversees the firm's strategic direction. DotLab's primary offering is the DotEndo test, a pioneering blood test designed for the detection of endometriosis. This non-invasive test significantly reduces the typical diagnosis delay of ten years, aimed at healthcare providers specializing in women's health.

Initially available in select U. S. markets, the company plans to expand its distribution as demand grows. DotLab generates revenue through direct sales of the DotEndo test to healthcare providers and clinics, employing a B2B model.

Revenue also includes partnerships with healthcare organizations to integrate the test into their services, ensuring accessibility while reflecting the innovative technology behind the test. DotLab's strategic growth plans include expanding the availability of the DotEndo test in additional markets in the U. S. and potentially other regions as demand increases.

The recent Series A funding of USD 10. 00 mn will support these initiatives, with further developments in product offerings aimed at enhancing women's health diagnostics.